Skip to main content
Submitted by Dr S. Patel on 5 June 2018
Image: Stock photo of colon over white t-shirt and dark jeans set against a pink background

Colorectal cancer is the 4th most common cause of deaths related to cancer worldwide. Lynch syndrome or HNPCC is one of most common genetic causes of Colon cancer. Here are a few questions to better understand Lynch syndrome and how we can screen for it.

1. What is the Lynch syndrome? Which genes are involved?

Lynch Syndrome is also known as hereditary non-polyposis colorectal cancer or HNPCC. It has a genetic disposition, hence the term hereditary and is known to be associated or  the causative factor for various cancers including endometrial (second most common), ovarian, stomach, small intestine, hepatobiliary tract, upper urinary tract, skin and brain. It is an autosomal dominant genetic condition, which means that the gene defect can be passed down to the child even if only one parent has the mutated gene. Just one copy of the mutated gene is sufficient to develop cancer. Gene mutation is the permanent alteration in the DNA sequence that makes up a gene. Individuals who are carriers of such a mutated gene have a higher than normal chance of developing colorectal and the various cancers mentioned above, often at a young age. The early age onset, sporadic occurrence and right-sided colon lesions are discovered to be characteristic to Lynch syndrome. [Image result for lynch syndrome]

Genes currently known to be susceptible for Lynch syndrome include MLH1, MSH2, MSH6, PMS2, and EPCAM. 

2. What are signs and symptoms of Lynch syndrome?

It is recommended that one watch out for any signs and symptoms of colon and endometrial cancer. People with Lynch syndrome have the following risk factors:

  • Personal history of multiple gastrointestinal polyposis.
  • History of colon or gastrointestinal cancer at a younger age, especially before age of 50 years. 
  • Personal history of any of the following cancers: endometrial cancer, ovarian cancer, kidney cancer, stomach cancer, small intestine cancer, liver cancer, sweat gland cancer (sebaceous carcinoma), skin or brain.
  • Family history of colon or endometrial cancer under the age of 50.
  • 1 or more 1st or 2nd degree relative with colorectal or Lynch syndrome associated cancers. 
  • 2 or more 1st or 2nd degree relative with colorectal or Lynch syndrome associated cancers.

3. How common is the Lynch syndrome in India?

There are several inherited syndromes that can lead to increased risk of colon cancer, of which Lynch syndrome is the most common.

Statistics says that approximately 3 out of every 100 colon cancers are due by Lynch syndrome. In India, the annual incidence rate of Colon cancer is 4.4 per 100,000 in men and 3.9 per 100,000 in women. Approximately 5% of all colon cancers are attributed to genetic predisposition of Lynch syndrome.

4. Does Lynch syndrome affect every generation?

Yes. It does not skip generations. Both sexes can have Lynch syndrome and it may pass to any of their children.

5. How can a mother prevent passing on the gene to her child? How does preimplantation genetic diagnosis work for Lynch syndrome?

Mother can prevent passing unwanted genes to her child by doing preimplantation genetic diagnosis (PGD). Preimplantation genetic diagnosis is the procedure used to identify any genetic defects in an embryo. Embryos are usually made via the in vitro fertilization (IVF), tested at day 5 and only the desired embryos free of genetic problems are implanted into the uterus. Since the procedure is carried out before implantation, a couple has the choice of whether they want to start the pregnancy or not.

PGS or preimplantation genetic screening, is a procedure where all the embryos (produced by IVF) are checked for genetic diseases, so that the best embryo is then selected.

6. How is Lynch syndrome diagnosed?

After the tumor has been found via physical examination and colonoscopy, Lynch syndrome can be confirmed via tumor tissue testing from a biopsy. This is carried out for any individual who is suspected of having Lynch syndrome.

The two tumor tissue tests available are:

  • Microsatellite instability (MSI) test where a dye is used to check for missing proteins.
  • Immunohistochemistry (IHC) test determines instability in the DNA sequence.

Genetic testing of blood samples is commonly done to check for heritable mutations. Molecular genetic testing is necessary to confirm diagnosis of Lynch syndrome.

7. When and when should one start screening for it?

Families with Lynch syndrome and family members tested positive for gene mutation and those who have not been tested, should start colonoscopy screening during their early 20s, or 2 to 5 years younger than the youngest person in the family with a diagnosis (whichever is earlier). 

  • Colonoscopy should be done every 1 or 2 years. If there are any polyps present, they can be detected and removed. This helps find any early cancers too. People known to carry one of the gene mutations may also be given the choice of having surgery to remove most of the colon as a prophylactic measure.
  • Women are also recommended to inform their Gynecologist and get a transvaginal ultrasound or endometrial biopsy done every year after the age of 30.

8. If a person has been detected with the HPNCC genes, what preventive/ prophylactic measures are offered to the person?

  • Subtotal colectomy with ileorectal anastomosis (i.e. removal of subtotal colon and to join with rectum) and after that there is surveillance for rectum.
  • Or total colectomy with permanent ileostomy (removal of entire large colon and small bowel is put outside abdominal wall to pass stool and flatus permanently). This operation may be considered for prophylaxis in selected mismatch repair (MMR) gene mutation carriers.
  • Women may choose to have a hysterectomy (removal of the womb) or oophorectomy (removal of the ovaries). Such measures are recommended only after women have completed their families and do not prefer regular screening.

9. How much does genetic testing cost?

Testing of MLH1 is around 30,000/ rupees in India. If you have Lynch syndrome, each of your children have a 50% chance of acquiring the mutated gene. Children over the age of 18 can undergo genetic testing.

10. Can Lynch syndrome also cause Breast cancer?

The estimates of an increased risk of breast cancer in Lynch syndrome is relatively small compared with the increased risks observed for colorectal and endometrial cancers. 

It has a risk of around 12%.

11. What is the prognosis for Lynch syndrome-associated cancers?

Prognosis for Lynch Syndrome is,

  • Ten-year survival was 87% after any cancer.
  • 91% if the first cancer was colorectal.
  • 98% if endometrial and 89% if ovarian cancer..

References:

  1. Indian Council of Medical Research http://www.icmr.nic.in/guide/cancer/Colorectal/
  2. https://www.cancer.net/cancer-types/lynch-syndrome
  3. MedIndia, network for Health. https://www.medindia.net/patientinfo/lynch-syndrome.htm
  4. American Pregnancy Association. www.americanpregnancy.org

 

Community

Stories

  • My cancer doesn't define who I am
    "I was originally diagnosed with locally advanced cancer, so that means it's advanced within in the chest. Mine was triple negative. It's the most aggressive form of cancer," she said. Her breast cancer diagnosis came in 2008. She found out about her metastatic breast cancer in January 2011, at 33 years old. "Two and half years after my original diagnosis, I found another lump," she said as she held back tears. "It varies from person to person. But my experience has been a bit of a roller…
  • Joan Lunden talks about her Breast Cancer
    How she shared the information with her kids and why - http://www.today.com/health/joan-lunden-how-i-told-my-kids-i-have-cancer-2D80186889 The choices she made in terms of treatment - http://www.people.com/article/joan-lunden-chemotherapy-cancer
  • Breast cancer drug Perjeta appears to extend patients lives
    According to reports from clinical trials, Roche’s breast cancer drug Perjeta displays “unprecedented” life-extending effects, helping patients live an average of 15.7 months longer than they would on chemotherapy and an older drug. 15.7 months is a significant amount of time for metastatic breast cancer patients, who are, on average, given two to three years to live after their diagnosis. Perjeta, then, has the capacity to increase that time by 50 to 75 percent.  http://www…
  • Heal Your Cancer
    Don’t fight cancer, heal it by attending to body, mind and spirit, says surgical oncologist Dr Vishal Rao. A child developing from an embryo in a mother’s womb is, in reality, a set of rapidly multiplying cells. But they are controlled and regulated. So, we choose to ‘love’ those cells. But when another set of cells multiply rapidly within our body, albeit haphazardly, we call it ‘Cancerous’! These cells are not foreign cells that have made an appearance from outside,…
  • “I was open to anything, just trying to find things to help me stay alive,” said Geoffrey Boycott
    Geoffrey Boycott describes how counting off his radiotherapy sessions like runs in cricket and Feng Shui helped him survive cancer http://www.telegraph.co.uk/sport/cricket/11080199/Geoffrey-Boycott-reve…
  • Mayo Clinic partners with IBM to match Cancer Patients with Clinical Trials
    Mayo Clinic unveiled today a partnership with IBM to harness the power of its Watson supercomputer to match patients with the right clinical trials. Starting early next year, Watson will initially enroll patients with breast, colorectal and lung cancers based on eligibility. There are 170,000 ongoing clinical trials around the world, however, according to the Center for Information and Study on Clinical Research Participation, only 6% are completed on time. Enrolling patients in the…
  • FDA approves first use of novel immune system drug for cancer
    This new class of drugs unleashes the body's immune system to fight tumors. This seems to solve a century-old mystery of how cancerous cells manage to evade the body's immune system. The drug which Merck will sell under the name of Keytruda was approved by patients with advanced melanoma who have exhausted other therapies.  http://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html?emc=eta1
  • Breast cancer specialist reports advance in treatment of triple-negative breast cancer that disproportionately affects younger women
    We hope that this means fewer women will relapse and die of their cancer, though the study is not large enough to prove this conclusively. Of the two agents we studied, we are more encouraged by the results from the addition of carboplatin, since it was associated with fewer and less concerning additional side effects than bevacizumab," Sikov explains.  William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's…
  • Do more for depressed cancer patients
    Clinical depression was much more prevalent among cancer patients than in the general population, where around 2% of people suffer from the mental illness at any point in time. Among cancer patients, clinical depression ranged from 13% in people with lung cancer to 6% in people with genitourinary cancer. The study's lead author Michael Sharpe, from Oxford University, said: "Major depression is really quite common in people with cancer and the perhaps surprising finding is that most of it goes…
  • Breast Cancer and Pregnancy - An Oncologist Shares
    Right and timely treatment can keep both mother and baby safe. Dr D.G. Vijay, Breast Cancer Specialist recalls a case of gestational breast cancer. Mrs. AK was overjoyed when her obstetrician told her that she was pregnant. She had been undergoing infertility treatment for a long time with no success. Only a few years ago, her mother had been diagnosed with breast cancer and she wished to see her grandchild before anything happened to her. But Mrs AK’s joy was short- lived as she…